OncoMark featured in The Sunday Times
Desmond O'Leary was impressed by OncoMarks' proof of concept data for their early stage breast cancer prognostic assay, named OncoMasTR. These data, the strong market opportunity and the experienced team leading the company, first attracted him to OncoMark and led to his appointment as CEO in August 2015.